16
Jun

GlaxoSmithKline spinout Convergence Pharmaceuticals reported some positive results for a Phase II study of its pain drug today, setting up a Phase III launch early next year as the biotech ponders a possible IPO in either the U.S. or the U.K. after some pioneers finally managed to break into the British exchange.

…read more

Source: GSK spinout Convergence ponders IPO leap as new wave of offerings crests

    

0 No comments